Annual Revenue
$65.49 M
+$17.86 M+37.48%
December 31, 2023
Summary
- As of February 8, 2025, PLX annual revenue is $65.49 million, with the most recent change of +$17.86 million (+37.48%) on December 31, 2023.
- During the last 3 years, PLX annual revenue has risen by +$2.60 million (+4.13%).
- PLX annual revenue is now at all-time high.
Performance
PLX Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Revenue
$17.96 M
+$4.49 M+33.29%
September 30, 2024
Summary
- As of February 8, 2025, PLX quarterly revenue is $17.96 million, with the most recent change of +$4.49 million (+33.29%) on September 30, 2024.
- Over the past year, PLX quarterly revenue has increased by +$7.61 million (+73.60%).
- PLX quarterly revenue is now -48.80% below its all-time high of $35.08 million, reached on June 30, 2023.
Performance
PLX Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
TTM Revenue
$45.67 M
+$7.61 M+20.01%
September 30, 2024
Summary
- As of February 8, 2025, PLX TTM revenue is $45.67 million, with the most recent change of +$7.61 million (+20.01%) on September 30, 2024.
- Over the past year, PLX TTM revenue has dropped by -$17.96 million (-28.22%).
- PLX TTM revenue is now -32.31% below its all-time high of $67.46 million, reached on June 30, 2023.
Performance
PLX TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
PLX Revenue Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +37.5% | +73.6% | -28.2% |
| 3 y3 years | +4.1% | +73.6% | -28.2% |
| 5 y5 years | +91.3% | +73.6% | -28.2% |
PLX Revenue Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +70.8% | -48.8% | +379.2% | -32.3% | +20.0% |
| 5 y | 5-year | at high | +70.8% | -48.8% | +379.2% | -32.3% | +20.0% |
| alltime | all time | at high | >+9999.0% | -48.8% | +272.8% | -32.3% | +875.5% |
Protalix BioTherapeutics Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $17.96 M(+33.3%) | $45.67 M(+20.0%) |
| Jun 2024 | - | $13.47 M(+259.5%) | $38.05 M(-36.2%) |
| Mar 2024 | - | $3.75 M(-64.3%) | $59.65 M(-8.9%) |
| Dec 2023 | $65.49 M(+37.5%) | $10.49 M(+1.4%) | $65.49 M(+2.9%) |
| Sep 2023 | - | $10.35 M(-70.5%) | $63.63 M(-5.7%) |
| Jun 2023 | - | $35.08 M(+265.8%) | $67.46 M(+64.0%) |
| Mar 2023 | - | $9.59 M(+11.3%) | $41.14 M(-13.6%) |
| Dec 2022 | $47.64 M(+24.2%) | $8.62 M(-39.2%) | $47.64 M(+0.1%) |
| Sep 2022 | - | $14.18 M(+62.0%) | $47.57 M(+4.7%) |
| Jun 2022 | - | $8.75 M(-45.6%) | $45.44 M(+5.4%) |
| Mar 2022 | - | $16.09 M(+88.2%) | $43.12 M(+12.4%) |
| Dec 2021 | $38.35 M(-39.0%) | $8.55 M(-29.1%) | $38.35 M(-22.2%) |
| Sep 2021 | - | $12.05 M(+87.6%) | $49.30 M(+2.6%) |
| Jun 2021 | - | $6.43 M(-43.2%) | $48.03 M(-8.6%) |
| Mar 2021 | - | $11.32 M(-41.9%) | $52.57 M(-16.4%) |
| Dec 2020 | $62.90 M(+15.0%) | $19.50 M(+80.7%) | $62.90 M(+2.8%) |
| Sep 2020 | - | $10.79 M(-1.6%) | $61.16 M(-5.4%) |
| Jun 2020 | - | $10.97 M(-49.3%) | $64.62 M(-1.9%) |
| Mar 2020 | - | $21.65 M(+21.9%) | $65.90 M(+20.5%) |
| Dec 2019 | $54.69 M(+59.7%) | $17.76 M(+24.6%) | $54.69 M(+15.7%) |
| Sep 2019 | - | $14.25 M(+16.3%) | $47.29 M(+4.2%) |
| Jun 2019 | - | $12.25 M(+17.3%) | $45.37 M(+19.5%) |
| Mar 2019 | - | $10.44 M(+0.8%) | $37.97 M(+10.9%) |
| Dec 2018 | $34.24 M(+62.4%) | $10.35 M(-16.1%) | $34.24 M(+21.5%) |
| Sep 2018 | - | $12.34 M(+155.0%) | $28.19 M(+20.6%) |
| Jun 2018 | - | $4.84 M(-27.9%) | $23.38 M(-6.1%) |
| Mar 2018 | - | $6.71 M(+56.0%) | $24.90 M(+18.1%) |
| Dec 2017 | $21.08 M(+129.1%) | $4.30 M(-42.8%) | $21.08 M(+11.8%) |
| Sep 2017 | - | $7.53 M(+18.4%) | $18.85 M(+17.9%) |
| Jun 2017 | - | $6.36 M(+120.1%) | $16.00 M(+40.2%) |
| Mar 2017 | - | $2.89 M(+38.8%) | $11.41 M(+24.0%) |
| Dec 2016 | $9.20 M(+110.8%) | $2.08 M(-55.4%) | $9.20 M(+29.2%) |
| Sep 2016 | - | $4.67 M(+164.0%) | $7.12 M(+88.1%) |
| Jun 2016 | - | $1.77 M(+160.5%) | $3.78 M(+12.9%) |
| Mar 2016 | - | $679.00 K(-49.2%) | $3.35 M(-156.9%) |
| Dec 2015 | $4.36 M | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | $1.34 M(0.0%) | -$5.89 M(+67.4%) |
| Jun 2015 | - | $1.34 M(-21.0%) | -$3.52 M(+62.3%) |
| Mar 2015 | - | $1.69 M(-116.5%) | -$2.17 M(-161.5%) |
| Dec 2014 | $3.52 M(-89.8%) | -$10.25 M(-376.6%) | $3.52 M(+4.1%) |
| Sep 2014 | - | $3.71 M(+38.0%) | $3.38 M(+11.5%) |
| Jun 2014 | - | $2.69 M(-63.6%) | $3.04 M(-11.1%) |
| Mar 2014 | - | $7.38 M(-171.1%) | $3.42 M(>+9900.0%) |
| Dec 2013 | - | -$10.39 M(-409.3%) | $0.00(-100.0%) |
| Sep 2013 | - | $3.36 M(+9.6%) | $10.44 M(-16.3%) |
| Jun 2013 | - | $3.06 M(-22.8%) | $12.47 M(-64.0%) |
| Mar 2013 | - | $3.97 M(+8166.7%) | $34.66 M(+0.7%) |
| Dec 2012 | $34.42 M(+1059.8%) | $48.00 K(-99.1%) | $34.42 M(-1.8%) |
| Sep 2012 | - | $5.39 M(-78.7%) | $35.06 M(+14.7%) |
| Jun 2012 | - | $25.26 M(+577.5%) | $30.57 M(+403.0%) |
| Mar 2012 | - | $3.73 M(+441.1%) | $6.08 M(-27.2%) |
| Dec 2011 | $2.97 M(-73.6%) | $689.00 K(-23.2%) | $8.35 M(-37.9%) |
| Sep 2011 | - | $897.00 K(+17.4%) | $13.44 M(-14.5%) |
| Jun 2011 | - | $764.00 K(-87.3%) | $15.73 M(-2.3%) |
| Mar 2011 | - | $6.00 M(+3.8%) | $16.10 M(+47.1%) |
| Dec 2010 | $11.24 M(+2797.9%) | $5.78 M(+81.5%) | $10.95 M(+96.9%) |
| Sep 2010 | - | $3.18 M(+179.1%) | $5.56 M(+134.0%) |
| Jun 2010 | - | $1.14 M(+34.7%) | $2.38 M(+92.4%) |
| Mar 2010 | - | $847.00 K(+118.3%) | $1.24 M(+218.3%) |
| Dec 2009 | $388.00 K(+158.7%) | $388.00 K(>+9900.0%) | $388.00 K(>+9900.0%) |
| Dec 2005 | $150.00 K(-65.1%) | - | - |
| Dec 2004 | $430.00 K(-87.9%) | - | - |
| Jun 2001 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2001 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Sep 2000 | - | $0.00(0.0%) | $43.40 K(-79.4%) |
| Jun 2000 | - | $0.00(0.0%) | $210.20 K(-84.9%) |
| Mar 2000 | - | $0.00(-100.0%) | $1.39 M(-60.8%) |
| Dec 1999 | $3.55 M(-55.8%) | $43.40 K(-74.0%) | $3.55 M(+1.2%) |
| Sep 1999 | - | $166.80 K(-85.9%) | $3.51 M(+5.0%) |
| Jun 1999 | - | $1.18 M(-45.4%) | $3.34 M(+54.6%) |
| Mar 1999 | - | $2.16 M | $2.16 M |
| Dec 1998 | $8.04 M | - | - |
FAQ
- What is Protalix BioTherapeutics annual revenue?
- What is the all time high annual revenue for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics annual revenue year-on-year change?
- What is Protalix BioTherapeutics quarterly revenue?
- What is the all time high quarterly revenue for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics quarterly revenue year-on-year change?
- What is Protalix BioTherapeutics TTM revenue?
- What is the all time high TTM revenue for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics TTM revenue year-on-year change?
What is Protalix BioTherapeutics annual revenue?
The current annual revenue of PLX is $65.49 M
What is the all time high annual revenue for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high annual revenue is $65.49 M
What is Protalix BioTherapeutics annual revenue year-on-year change?
Over the past year, PLX annual revenue has changed by +$17.86 M (+37.48%)
What is Protalix BioTherapeutics quarterly revenue?
The current quarterly revenue of PLX is $17.96 M
What is the all time high quarterly revenue for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high quarterly revenue is $35.08 M
What is Protalix BioTherapeutics quarterly revenue year-on-year change?
Over the past year, PLX quarterly revenue has changed by +$7.61 M (+73.60%)
What is Protalix BioTherapeutics TTM revenue?
The current TTM revenue of PLX is $45.67 M
What is the all time high TTM revenue for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high TTM revenue is $67.46 M
What is Protalix BioTherapeutics TTM revenue year-on-year change?
Over the past year, PLX TTM revenue has changed by -$17.96 M (-28.22%)